fbpx
Pipeline

ATA3219

ATA3219: Developing Off-the-Shelf Allogeneic CD19 Program for B-Cell Malignancies, With IND Expected in Q4 2022

  • Academic program generated proof of principle for EBV T-cell platform potential to generate off-the-shelf, allogeneic CAR T immunotherapies
  • ATA3219: Next-generation off-the-shelf, allogeneic CD19-1XX CAR+ EBV T-cell immunotherapy containing a modified CD3ζ signaling domain, 1XX.

Curran KJ, Sauter CS, Kernan NA, et al. Durable remission following “Off‐the‐Shelf” Chimeric Antigen Receptor (CAR) T‐cells in patients with relapse/refractory (R/R) B‐cell malignancies. Biol Blood Marrow Transplant. 2020;26(3):S89.
IND = Investigational New Drug

ATA3219

Program/Indication Preclinical Phase 1 Phase 2 Phase 3
ATA3219: B-cell malignancies
  • Target: CD19
  • Technologies: Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic
Program/Indication Phase
ATA3219: B-cell malignancies Preclinical
  • Target: CD19
  • Technologies: Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic

Next-Generation CAR T Technology

Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.
View Next-Generation CAR T